Catalyst Dossier · compiled by CeliA 🧫

Omeros Corporation (OMER)

Pharmaceutical Preparations · market cap $744M

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-13

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

The catalyst path

2026-08-13Earningsimp 5/10
2026-12-15 (est.)Phase 2 · OMS906 study drugimp 7/10

Pipeline

Asset	Phase	Indication
OMS103HP	Phase 3	Anterior Cruciate Ligament Reconstruction
OMS201	Phase 2	Urinary Calculi
OMS103HP-S	Phase 3	Meniscal Tear
OMS721	Phase 2	Thrombotic Microangiopathies
OMS906 study drug	Phase 2	Paroxysmal Nocturnal Hemoglobinuria
OMS302	Phase 3	Intraocular Lens Replacement
OMS302-PE	Phase 2	Cataract Extraction
OMS906	Phase 2	Paroxysmal Nocturnal Hemoglobinuria
Phenylephrine HCl	Phase 3	Unilateral Cataract Extraction
OMS302 Solution	Phase 2	Cataract
Biological: narsoplimab	Phase 2	Thrombotic Microangiopathies
OMS643762	Phase 2	Schizophrenia

Price & technical context

3-month

-23.2%

6-month

-45.3%

12-month

+212.5%

52-wk range

$3.08–$17.18

vs 50-day MA

-21.2%

vs 200-day MA

-10.5%

Realized vol

133.8%

Max drawdown

-75.6%

Daily closes through 2026-07-02. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for OMER (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 12 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.